NASDAQ:BNTX - Nasdaq - US09075V1026 - ADR - Currency: USD
There's no need to track down complicated and obscure businesses. Some of the market's best income-producing stocks are hiding in plain sight.
PFE beats first-quarter estimates for earnings but misses the same for sales. It maintains 2025 guidance.
The President Donald Trump administration's request for Novavax Inc. to conduct new clinical trials for its COVID-19 vaccine has created uncertainty across the vaccine industry, potentially affecting other manufacturers.
Summit Therapeutics highlights China approval of Akeso's ivonescimab for NSCLC, with enrollment ongoing for Phase 3 HARMONi-7 trial.
While Akeso (AKESF) and Summit Therapeutics’ (SMMT) ivonescimab, a rival to Merck’s (MRK) Keytruda, won approval in China this week, the data on patient survival did not meet analyst expectations, Jonathan Wosen of STAT reports. In its submission to regulators, Akeso included data on patient survival, disclosing that an interim analysis following 157 patient deaths found that participants on ivonescimab had a roughly 22% reduced risk of death, with a hazard ratio of 0.784, a company spokesperson
Pipeline companies remain well positioned despite the current disruption in the energy markets. At the same time, demand for natural gas is growing. This is coming from the increased power consumption stemming from artificial intelligence (AI), as well as from export demand from Mexico and for LNG (liquified natural gas) to Asia and Europe.
Mentions: SMMT
MAINZ, Deutschland, 24. April 2025 (GLOBE NEWSWIRE) -- BioNTech SE (Nasdaq: BNTX, „BioNTech“ oder „das Unternehmen“) wird auf der diesjährigen Jahrestagung...
MAINZ, Germany, April 24, 2025 -- BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”) will present data for selected assets from its diversified...
BioNTech is on the rise after Summit Therapeutics unveiled promising results for its PD-1- and VEGF-blocking drug.
Nobody has more information about a company than its insiders, especially its executive management team. On April 8, Summit Therapeutics' co-CEOs, Robert Duggan and Maky Zanganeh, each exercised warrants, financial instruments that grant their holders the right (but not the obligation) to acquire a company's shares at a predetermined price before a particular date. Do Summit Therapeutics' prospects -- beyond this recent development -- justify investing in the stock today?
MAINZ, Deutschland, 22. April 2025 (GLOBE NEWSWIRE) -- BioNTech SE (Nasdaq: BNTX, „BioNTech“ oder „das Unternehmen“) wird am Montag, den 5. Mai 2025, die...
MAINZ, Germany, April 22, 2025 (GLOBE NEWSWIRE) -- BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”) will announce its financial results for the...
Kennedy singled out the Novavax COVID-19 shot's single-antigen composition as the reason behind the delay in granting full approval.
From vaccines to fluoride and beef tallow, here's where Robert F. Kennedy Jr. is making changes to health care.
We recently published a list of 12 Best German Stocks to Buy According to Hedge Funds. In this article, we are going to take a look at where BioNTech SE (NASDAQ:BNTX) stands against other best German stocks to buy according to hedge funds. Germany’s economy is facing continued weakness. According to a report published by […]
We recently published a list of 12 Best German Stocks to Buy According to Hedge Funds. In this article, we are going to take a look at where Deutsche Bank Aktiengesellschaft (NYSE:DB) stands against other best German stocks to buy according to hedge funds. Germany’s economy is facing continued weakness. According to a report published […]
We recently published a list of 11 Best Engineering Stocks to Invest in Now. In this article, we are going to take a look at where Quanta Services Inc. (NYSE:PWR) stands against other best engineering stocks to invest in now. The global engineering services market was valued at $3.26 trillion in 2023, as reported by […]
Moderna Inc. shares plunged after the resignation of Peter Marks, a top regulator at the US Food and Drug Administration who had long overseen approvals of vaccines and other biological drugs.
For the current year, BioNTech projected revenue of 1.7 billion euros to 2.2 billion euros, below the market consensus of 2.54 billion euros and a fall from last year's 2.75 billion euros.
Onkologie-Pipeline weiterentwickelt mit mehr als 20 aktiven klinischen Phase-2- und Phase-3-Studien mit strategischem Fokus auf zwei tumorübergreifende...
Advanced oncology pipeline including more than 20 active Phase 2 and Phase 3 clinical trials with a strategic focus on two priority pan-tumor programs:...